Skip to content

Dr. Abicca Irene

Abicca Irene

Linea di ricerca:

Glaucoma and anterior segment with ocular annexes
Unità di ricerca:
UR Anterior segment with ocular adnexa
Principali specializzazioni:
CATARACT, KERATOCONUS

Medical activity: Works at IRCCS Foundation G.B. Bietti in the offices of Via Livenza, 3 and Via di Santo Stefano Rotondo 6, at the British Hospital, Rome

Scientific publication: PubMed

linkedin: Irene Abicca

E-mail: irene.abicca@fondazionebietti.it

  • 2011: Degree in Medicine and Surgery at University “La Sapienza” of Rome, summa cum laude (Thesis: “Clinical and epidemiological study of intermediate uveitis in childhood”);
  • 2016: Short term fellowship course in cataract surgery at Sahai Hospital, Jaipur, India;
  • 2017: Residency in Ophthalmology in 2017 at University “La Sapienza” of Rome, summa cum laude (Thesis: “Neuroinflammation in allergy: a conjunctival allergen challenge study in allergi rhinoconjunctivitis”);
  • 2017-2018: Research scholarship at University “La Sapienza” of Rome ( Changes of NGF pathway in allergic rhinoconjunctivitis: a study for the identification of new clinical biomarker and therapeutic target);
  • 2019-2021: Master in Statistical Methods for research and biomedical practice.

AIMO (Associazione Italiana Medici Oculisti)

SIUMIO (Società Italiana Uveiti e Malattie Infiammatorie Oculari)

  • June-August 2017:sub-investigator in the clinical trial “A 2 week, randomized, double-masked, controlled, parallel group study to evaluate tolerability, safety, permancence on the ocular surface and efficacy of two concentrations of Lubricin (20 and 50 µg/mL) eye drops versus sodium hyaluronate (HA) 0.18% eye drops (Vismed) in patients with ocular discomfort following refractive surgery;
  • November 2020-May 2021: sub-investigator in the clinical trial “CHL.3/01-2019/M “A prospective, observer-masked, randomized clinical trial to investigate and compare the clinical efficacy of chloroprocaine 3% gel and tetracaine 0.5% eye drop as topical anesthetics in phacoemulsification”;
  • June 2021-ongoing: sub-investigator in the clinica trial “Assessment of the effect and tolerability of RD03/2016 (levofloxacin; ketorolac trometamol 0,5+0,5% W/v eye drops solution for the treatment of bacterial conjuntivitis in adults: a multicenter, randomized, blinded-assessor,phase II non inferiority study- MIRAKLE (LEVOKETO)
  • European Journal of Ophthalmology;
  • Scientific Reports.
Skip to content